Clinical Trials Browser

nimotuzumab × 1 year × Clear all

NCT07445048 2026-04-17

Postoperative Radiotherapy Combined With Nimotuzumab Followed by Benmelstobart in High-Risk Patients With Head and Neck Squamous Cell Carcinoma

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07535567 2026-04-17

NimoBenSeq

Phase 2/3 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07457528 2026-03-11

Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC

Phase 2 Recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04821778 2026-01-21

Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

Phase 3 Recruiting

Gastrointestinal

Esophageal Neoplasms

NCT04821843 2026-01-21

Neoadjuvant Treatment Modalities in Esophageal Cancer

Phase 3 Recruiting

Gastrointestinal

Esophageal Neoplasms

NCT07354984 2026-01-21

PIONEER-HN

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07353723 2026-01-20

Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer

Phase 2 Recruiting

Pathologic Complete Response, Head and Neck Neoplasms

NCT07333274 2026-01-12

Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma

Phase 3 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07312578 2025-12-31

Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma

Phase 2 Enrolling by invitation

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07277452 2025-12-11

NOTABLE-309

Phase 2 Not yet recruiting

Gastrointestinal

Pancreatic cancer, adult

NCT06770452 2025-09-23

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

Phase 2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT06509009 2025-09-19

Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT07070479 2025-09-18

Combination Therapy for PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma: A Bayesian Adaptive Phase II Trial

Phase 2 Recruiting

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT07053735 2025-07-08

An Exploratory Clinical Study of Nimotuzumab in Bladder - Sparing Chemoradiotherapy for Muscle - Invasive Bladder Cancer

Phase 1 Not yet recruiting

Urinary Bladder Neoplasms, Neoplasms

NCT06048913 2025-07-04

Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Treatment Esophageal Cancer in Old Age

Phase 2 Completed

Gastrointestinal

Esophageal Neoplasms

NCT06988956 2025-05-25

Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma

Phase 2 Recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06912711 2025-05-21

TN Induction and Adjuvant Therapy for Resectable Local Recurrent Nasopharyngeal Carcinoma

Phase 2 Recruiting

Nasopharyngeal Carcinoma

NCT04456322 2025-05-14

Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

Nasopharyngeal Carcinoma

NCT06938503 2025-04-22

AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer

Phase 2 Not yet recruiting

Gastrointestinal

Pancreatic cancer, adult